CYP1A1 and malignant hypertension: Furthermore, we reported repeatedly that the development of ANG II-dependent malignant hypertension in Cyp1a1-Ren-2 transgenic rats is accompanied by decreased intrarenal availability of EETs [34,40,43–45].